Monoclonal Antibodies in Multiple Myeloma: A New Wave of the Future

In 2015, two monoclonal antibodies were approved for the treatment of relapsed or refractory multiple myeloma (RRMM), elotuzumab and daratumumab. Elotuzumab is a monoclonal IgG- κ antibody directed against SLAMF7, a cell surface receptor involved in natural killer cell activation. Daratumumab is a monoclonal IgG-κ antibody that binds to CD38, a transmembrane protein found on the surface of myeloma cells responsible for cellular adhesion and ectoenzymatic activity. Both el otuzumab and daratumumab act through recruitment of the immune system to enhance cellular cytotoxicity directed against myeloma cells.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Review Article Source Type: research